<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014755</url>
  </required_header>
  <id_info>
    <org_study_id>199/15796</org_study_id>
    <secondary_id>FHCRC-1164.00</secondary_id>
    <nct_id>NCT00014755</nct_id>
  </id_info>
  <brief_title>Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and&#xD;
      cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC)&#xD;
      transplantation in patients with multiple sclerosis.&#xD;
&#xD;
      II. Determine the disease response of patients treated with this regimen. III. Determine the&#xD;
      safety and efficacy of filgrastim (G-CSF) for PBSC mobilization in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a multicenter study. Patients receive oral prednisone on days 0-10.&#xD;
      Beginning on day 1, patients undergoing autologous peripheral blood stem cell (PBSC)&#xD;
      transplantation receive filgrastim (G-CSF) subcutaneously daily until leukapheresis is&#xD;
      completed. Leukapheresis begins on approximately day 4 and continues until adequate CD34+&#xD;
      PBSC are collected.&#xD;
&#xD;
      PBSC are collected from syngeneic donors in a similar manner. Patients undergo total-body&#xD;
      irradiation twice daily on days -5 and -4. Patients receive cyclophosphamide IV on days -3&#xD;
      and -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5. Patients undergo&#xD;
      autologous or syngeneic PBSC transplantation on day 0. Following PBSC transplantation,&#xD;
      patients receive oral prednisone on days 7-30 and G-CSF IV daily beginning on day 0 and&#xD;
      continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed at 30, 80, and 90 days, monthly for 6 months, and then at 1 and 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>35</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>irradiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of rapidly progressive multiple sclerosis (MS) by Proser criteria and at high&#xD;
        risk for a fatal outcome or severe disability with one of the following:&#xD;
&#xD;
          -  Primary progressive disease&#xD;
&#xD;
          -  Relapsing/remitting disease with 2 or more attacks in 2 years&#xD;
&#xD;
          -  Secondary progressive disease&#xD;
&#xD;
        Extended disability status scale (EDSS) between 5.0 and 8.0 with deterioration in the EDSS&#xD;
        of 1 or more points over the past year&#xD;
&#xD;
        More than 60 days since relapse of MS&#xD;
&#xD;
        No evidence of myelodysplasia&#xD;
&#xD;
        Sibling donor proven to be an identical twin by ABO typing, HLA typing, and VNTR analysis&#xD;
        (for syngeneic transplantation)&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Radiotherapy: No prior total-lymphoid irradiation&#xD;
&#xD;
        Other: No other concurrent investigational agents&#xD;
&#xD;
        --Patient Characteristics-- Hepatic: No hepatic impairment that would preclude high-dose&#xD;
        immunosuppressive therapy&#xD;
&#xD;
        Renal: No renal impairment that would preclude high-dose immunosuppressive therapy&#xD;
&#xD;
        Cardiovascular: No cardiac impairment that would preclude high-dose immunosuppressive&#xD;
        therapy&#xD;
&#xD;
        Pulmonary: No pulmonary impairment that would preclude high-dose immunosuppressive therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No neurologic impairment that would preclude high-dose immunosuppressive therapy&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No active malignancy&#xD;
&#xD;
          -  No other illness that would severely limit life expectancy&#xD;
&#xD;
          -  No medical or psychiatric conditions that would preclude study&#xD;
&#xD;
          -  No history of hypersensitivity to murine proteins or E. coli-derived proteins&#xD;
&#xD;
          -  No demonstrated lack of compliance with prior medical care&#xD;
&#xD;
          -  Able to undergo an MRI scan&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Nash</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Barnard Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2001</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>April 10, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>multiple sclerosis</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

